Company Overview
DNAtrix is a clinical stage, biotechnology company developing virus-driven immunotherapies for cancer. DNAtrix’s lead product, DNX-2401, is a conditionally replicative oncolytic virus being studied in clinical trials for recurrent glioblastoma, an aggressive form of brain cancer. The company’s pipeline includes viruses armed with potent immunomodulatory molecules to treat cancer.

Company Presentations

1:30 PM–1:45 PM Jun 21, 2017 (America - Los Angeles)

Company Presentation Theater 1